Modern head Stephen Hoge, from United Statesdollarser third or the discussion of whether he needs more doses of the vaccine, came a statement that did not give much explanation to the subject.
3. for the growing debate over whether to get the last dose of vaccine, or more if needed Yahoo Finance
“We really don’t know,” Hoge said in a statement to . In addition, it is still unclear who will benefit most from the extra dose.
Experts are uneasy about the approaching winter months:
According to Hoge, if it is believed that an additional dose will provide better protection, it seems highly likely that a third dose will be administered in late autumn and winter when respiratory diseases and therefore cases increase.
Health experts have been dreading the approaching cold weather for some time, which they think will once again be padlocked in cases across the country. Considering the high vaccination rates, the severity of these cases can be quite mild; However Delta
The variant continues to be proven to cause padollaration in cases, and in addition, until the end of the year. wrap new vayrandollar
There’s also the fact that can derive and spread. For this reason, some experts believe that the current vaccine level is sufficient and that thanks to the vaccine, COVID-19 memory cells that learn how to fight should be trusted. However, some experts argue that antibody levels, which are at their highest after vaccination, should be taken into account to determine when to supplement.
Hoge said, “ We think the debate about whether to base memory cells or antibodies is wrong. Each both are important.“, stating that he thinks that both perspectives should be taken into account.
Awaiting FDA approval for the booster dose:
According to data released Wednesday , from first dose compared to one year later 8 months later provides better protection against padollaring incidents; however, the most benefit is for the booster dose. FDA will see immunosuppressed persons and the elderly already authorized.
In addition, Moderna, which corresponds to half the original dose 50 micrograms is trying to get FDA approval for the booster dose.
In addition to all this, Moderna is considering increasing potential production as a result of a lower booster dose.
Since COVID-19 entered the vaccine industry, the company’s once-small biotech stock has skyrocketed. Hoge said about this situation, “ As a company, we produce zeredollarse, said “and” We’re doing as much as we can, and we’ve done it for most of the year – and we will for most of next year. We are trying to scale up and invest in production to produce more doses.” he added.